Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kin

详细信息    查看全文

• 作者：Anthony D. William ; Angeline C.-H. Lee ; Ste虂phanie Blanchard ; Anders Poulsen ; Ee Ling Teo ; Harish Nagaraj ; Evelyn Tan ; Dizhong Chen ; Meredith Williams ; Eric T. Sun ; Kee Chuan Goh ; Wai Chung Ong ; Siok Kun Goh ; Stefan Hart ; Ramesh Jayaraman ; Mohammed Khalid Pasha ; Kantharaj Ethirajulu ; Jeanette M. Wood ; Brian W. Dymock
• 刊名：Journal of Medicinal Chemistry
• 出版年：2011
• 出版时间：July 14, 2011
• 年：2011
• 卷：54
• 期：13
• 页码：4638-4658
• 全文大小：1512K
• 年卷期：v.54,no.13(July 14, 2011)
• ISSN：1520-4804

文摘

Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2^V617F), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treatment for myelofibrosis (MF). Herein, we describe the design and synthesis of a series of small molecule 4-aryl-2-aminopyrimidine macrocycles and their biological evaluation against the JAK family of kinase enzymes and FLT3. The most promising leads were assessed for their in vitro ADME properties culminating in the discovery of 21c, a potent JAK2 (IC₅₀ = 23 and 19 nM for JAK2^WT and JAK2^V617F, respectively) and FLT3 (IC₅₀ = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC₅₀ = 1280 and 520 nM, respectively). Further profiling of 21c in preclinical species and mouse xenograft and allograft models is described. Compound 21c (SB1518) was selected as a development candidate and progressed into clinical trials where it is currently in phase 2 for MF and lymphoma.